Last Friday the Johnson and Johnson’s Covid 19 vaccine resumed as the momentary pause that was imposed on it by the U.S. Food and Drug Administration was withdrawn. But this time the vaccine has come with a label on it notifying about its risk of blood clots.
Johnson And Johnson’s Covid19 Vaccines Resume
This was possible only with the support of some special experts of the Centers for Disease Control and Prevention who gave proposals to resume the vaccine.
CDC concluded that the importance of the vaccine in protecting people from deaths and hospitalizations is much more than the threat of blood clots, which are exceptional and restricted to only one section of the population that is young females.
Johnson and Johnson’s vaccines have some advantages over the other two vaccines from Moderna and Pfizer-BioNtech. J&J vaccines are easy to store as they don’t need specifically cold storage and it is just only one single shot which lessens the hassle of going twice for vaccination.
There was a poll for voting in which 10 voted in favor and 4 opposed. The ones those who opposed had a strong opinion about the high risk for younger women, less than 50 in age, and it was recommended that they should rather opt for the other vaccines.
The recommendations by the panel reached the Centers for Disease Control and Prevention, just after a week of the pause of the J&J vaccine. It went for approval to Rochelle Walensky, CDC director.
An analysis was made to measure the risk and advantages for every one million shots of J&J vaccines administered, by the Advisory Committee on Immunization Practices of CDC. The findings of this analysis were that out of 1 million people 13 women of age 18 to 49 would be at the risk of blood clots whereas 12 demises, 127 ICU admits, 657 hospitalizations related to Covid can be avoided. There would be 2 cases of the blood clot in women who are 50 and above and 593 deaths, 1292 ICU admissions, and 4794 hospitalizations can be blocked. For men, there would be only 2 cases of the blood clot within the age of 18 to 49, but 11 casualties, 114 ICU admissions, 601 hospitalizations can be avoided. There won’t be any blood clot cases in older men who are 50 and above whereas 708 death cases, 5513 hospitalizations, and 1485 ICU admissions can be avoided.
The pause was imposed on the one-shot vaccine after 6 U.S. reports about the deadly and unusual blood clots occurring only in women. On Friday in CDC’s meeting, one of the researchers presented 9 more similar cases, which makes a total of 15 cases with blood clots and all were women out of which 13 were of age 18 to 49. These cases are so severe that 3 of them have deceased, 7 are still hospitalized and 4 are in the ICU as confirmed by the scientist of CDC.
Before the pause, almost more than 4 million J&J vaccines were already administered in the United States.
The chief medical officer of J&J, Dr. Joanne Waldstreicher reported that J&J has agreed with the U.S. Food and Drug Administration to put a label on the vaccine mentioning its effects of the blood clot on women between 18 and 49.
These clots are referred to as thrombosis with thrombocytopenia syndrome by the ACIP. These clots can form in the brain or any other part of the body.
CNN has reported that according to some blood specialists these clots might be occurring from an odd immune system that makes the platelets to cluster together to form clots.
These clots definitely need a special kind of cure. The blood specialist from Johns Hopkins University will brief the panel of ACIP about the treatments of these deadly clots. Some blood thinners like heparin and an immune treatment IVIG might be helpful for dissolving these clots.